SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

14 Nov 2021 Evaluate
The revenue for the September 2021 quarter is pegged at Rs. 1219.08 millions, about 12.31% up against Rs. 1085.50 millions recorded during the year-ago period.The Net Loss for the quarter ended September 2021 is Rs. -207.43 millions as compared to Net Loss of Rs. -249.59 millions of corresponding quarter ended September 2020Operating profit for the quarter ended September 2021 decreased to 92.12 millions as compared to 183.13 millions of corresponding quarter ended September 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 1219.08 1085.50 12.31 2174.45 2275.71 -4.45 4506.95 4812.09 -6.34
Other Income 17.67 9.32 89.59 48.90 22.03 121.97 64.75 242.77 -73.33
PBIDT 92.12 183.13 -49.70 167.81 419.12 -59.96 643.62 336.08 91.51
Interest 98.93 133.31 -25.79 207.72 269.16 -22.83 513.36 41.59 1134.34
PBDT -6.81 49.82 -113.67 -39.91 149.96 -126.61 130.26 294.49 -55.77
Depreciation 200.62 299.41 -32.99 401.70 595.84 -32.58 1088.99 1179.07 -7.64
PBT -207.43 -249.59 -16.89 -441.61 -445.88 -0.96 -958.73 -884.58 8.38
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -207.43 -249.59 -16.89 -441.61 -445.88 -0.96 -958.73 -884.58 8.38
Equity 408.16 408.16 0.00 408.16 408.16 0.00 408.16 408.16 0.00
PBIDTM(%) 7.56 16.87 -55.21 7.72 18.42 -58.10 14.28 6.98 104.47

Orchid Pharma Share Price

570.50 6.40 (1.13%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×